Wall Street brokerages expect Teladoc, Inc. (NYSE:TDOC) to post earnings of ($0.50) per share for the current quarter, according to Zacks. Thirteen analysts have issued estimates for Teladoc’s earnings, with the lowest EPS estimate coming in at ($0.58) and the highest estimate coming in at ($0.22). Teladoc reported earnings per share of ($0.33) in the same quarter last year, which suggests a negative year-over-year growth rate of 51.5%. The business is scheduled to report its next quarterly earnings results after the market closes on Wednesday, November 1st.
On average, analysts expect that Teladoc will report full year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.63) to ($0.94). For the next fiscal year, analysts expect that the company will post earnings of ($1.16) per share, with EPS estimates ranging from ($1.72) to ($0.35). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Teladoc.
Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). The firm had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. Teladoc’s quarterly revenue was up 68.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.38) earnings per share.
Several research firms recently weighed in on TDOC. KeyCorp reissued a “buy” rating and issued a $37.00 target price on shares of Teladoc in a research note on Sunday, September 17th. Robert W. Baird cut shares of Teladoc from an “outperform” rating to a “neutral” rating and raised their target price for the company from $14.00 to $36.00 in a research note on Monday, September 18th. Zacks Investment Research cut shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $32.00 price objective on shares of Teladoc in a research report on Friday, July 14th. Finally, TheStreet cut shares of Teladoc from a “c-” rating to a “d” rating in a research report on Monday, July 3rd. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $38.00.
COPYRIGHT VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Expected to Announce Earnings of -$0.50 Per Share” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/teladoc-inc-tdoc-expected-to-announce-earnings-of-0-50-per-share.html.
Teladoc (TDOC) traded down 0.73% during mid-day trading on Monday, hitting $34.05. 518,966 shares of the company traded hands. Teladoc has a one year low of $14.00 and a one year high of $37.55. The stock’s market capitalization is $1.93 billion. The company’s 50-day moving average is $33.27 and its 200-day moving average is $33.27.
In other news, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the sale, the insider now owns 33,008 shares of the company’s stock, valued at $1,020,607.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Mark Hirschhorn sold 10,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The disclosure for this sale can be found here. In the last three months, insiders sold 168,806 shares of company stock valued at $5,430,382. 4.47% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. FMR LLC boosted its position in shares of Teladoc by 1.3% in the second quarter. FMR LLC now owns 8,209,737 shares of the health services provider’s stock valued at $284,879,000 after acquiring an additional 106,500 shares during the period. BlackRock Inc. boosted its position in shares of Teladoc by 42.9% in the second quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after acquiring an additional 1,154,852 shares during the period. Vanguard Group Inc. boosted its position in shares of Teladoc by 11.5% in the second quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after acquiring an additional 314,646 shares during the period. Alliancebernstein L.P. boosted its position in shares of Teladoc by 22.2% in the second quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after acquiring an additional 507,390 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Teladoc by 65.8% in the second quarter. JPMorgan Chase & Co. now owns 2,663,600 shares of the health services provider’s stock valued at $92,426,000 after acquiring an additional 1,057,065 shares during the period. 94.41% of the stock is owned by institutional investors.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Get a free copy of the Zacks research report on Teladoc (TDOC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.